[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE200000573A - Asendatud indoolalkaanhapped - Google Patents

Asendatud indoolalkaanhapped

Info

Publication number
EE200000573A
EE200000573A EEP200000573A EEP200000573A EE200000573A EE 200000573 A EE200000573 A EE 200000573A EE P200000573 A EEP200000573 A EE P200000573A EE P200000573 A EEP200000573 A EE P200000573A EE 200000573 A EE200000573 A EE 200000573A
Authority
EE
Estonia
Prior art keywords
indolealkanoic acids
substituted
substituted indolealkanoic
acids
indolealkanoic
Prior art date
Application number
EEP200000573A
Other languages
English (en)
Inventor
L. Jones Michael
Gunn David
Howard Jones John
C. Van Zandt Michael
Original Assignee
The Institutes For Pharmaceutical Discovery, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institutes For Pharmaceutical Discovery, Llc filed Critical The Institutes For Pharmaceutical Discovery, Llc
Publication of EE200000573A publication Critical patent/EE200000573A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EEP200000573A 1998-03-31 1999-03-31 Asendatud indoolalkaanhapped EE200000573A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8014398P 1998-03-31 1998-03-31
PCT/US1999/007116 WO1999050268A2 (en) 1998-03-31 1999-03-31 Substituted indolealkanoic acids

Publications (1)

Publication Number Publication Date
EE200000573A true EE200000573A (et) 2002-04-15

Family

ID=22155536

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000573A EE200000573A (et) 1998-03-31 1999-03-31 Asendatud indoolalkaanhapped

Country Status (29)

Country Link
US (9) US6214991B1 (et)
EP (1) EP1066283B1 (et)
JP (2) JP3494990B2 (et)
KR (1) KR100584650B1 (et)
CN (1) CN1205207C (et)
AP (1) AP2000001929A0 (et)
AT (1) ATE269861T1 (et)
AU (1) AU774929B2 (et)
BG (1) BG65446B1 (et)
BR (1) BR9909358A (et)
CA (1) CA2383983C (et)
CZ (1) CZ300706B6 (et)
DE (1) DE69918278T2 (et)
EE (1) EE200000573A (et)
ES (1) ES2224632T3 (et)
HU (1) HUP0101672A3 (et)
ID (1) ID27884A (et)
IL (2) IL138711A0 (et)
MX (1) MXPA02003122A (et)
NO (1) NO20004900L (et)
NZ (1) NZ507172A (et)
OA (1) OA11622A (et)
PL (1) PL201645B1 (et)
SK (1) SK7522001A3 (et)
TR (1) TR200002869T2 (et)
TW (1) TWI243163B (et)
WO (1) WO1999050268A2 (et)
YU (1) YU59600A (et)
ZA (1) ZA200005577B (et)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224632T3 (es) * 1998-03-31 2005-03-01 The Institutes For Pharmaceutical Discovery, Inc. Acidos indolalcanoicos sustituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU5960300A (en) * 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU2001259668A1 (en) * 2000-05-09 2001-11-20 The Institute For Pharmaceutical Discovery Llc Methods for testing compounds useful for treating diabetic complications
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE356623T1 (de) 2002-01-18 2007-04-15 Aryx Therapeutics 5-ht3-rezeptorantagonisten und verwendungsverfahren
AU2003256926A1 (en) * 2002-07-26 2004-02-16 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
CA2395871A1 (en) * 2002-07-26 2004-01-26 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
US7186746B2 (en) * 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
ES2268480T3 (es) 2002-12-10 2007-03-16 Wyeth Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509238A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2006510672A (ja) 2002-12-10 2006-03-30 ワイス プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体
DK1569901T3 (da) 2002-12-10 2009-02-16 Wyeth Corp Aryl-, aryloxy- og alkoxysubstituerede 1H-indol-3-yl-glyoxylsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
WO2004098498A2 (en) 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
CN1812977A (zh) * 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
KR20060054410A (ko) * 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 플라비비리다에에 대한 2고리 이미다졸 유도체
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200630327A (en) * 2004-10-28 2006-09-01 Inst For Pharm Discovery Inc Substituted phenylalkanoic acids
MX2007008587A (es) * 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
KR101644170B1 (ko) 2008-01-18 2016-08-01 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) * 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
GB2457040A (en) * 2008-01-30 2009-08-05 Oxagen Ltd 1-Acetic acid indole derivatives with PGD2 activity
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
EP3192796B1 (en) * 2010-07-16 2019-09-04 The Trustees of Columbia University in the City of New York Aldose reductase inhibitors and uses thereof
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
PL3757107T3 (pl) 2016-06-21 2024-03-18 The Trustees Of Columbia University In The City Of New York Związki 4-okso-3,4-dihydrotieno[3,4-d]pirydazyny jako inhibitory reduktazy aldozy i sposoby ich użycia
HRP20240840T1 (hr) 2017-07-28 2024-10-11 Applied Therapeutics, Inc Pripravci i postupci za liječenje galaktozemije
US11530186B2 (en) 2018-03-29 2022-12-20 H. Lee Moffitt Cancer Center and Research Center Institute, Inc. Inhibitors for the β-catenin / T-cell factor protein-protein interaction
BR112021021939A2 (pt) 2019-05-07 2022-02-22 Ucl Business Ltd Tratamento e detecção de neuropatias herdadas e distúrbios associados

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4960785A (en) * 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
EP0427860A1 (en) 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
GB9011335D0 (en) * 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5391551A (en) 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9409583D0 (en) 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
ES2224632T3 (es) 1998-03-31 2005-03-01 The Institutes For Pharmaceutical Discovery, Inc. Acidos indolalcanoicos sustituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
US20010016661A1 (en) 2001-08-23
JP3494990B2 (ja) 2004-02-09
US7659269B2 (en) 2010-02-09
ZA200005577B (en) 2002-02-11
CZ20003607A3 (cs) 2001-03-14
JP2002509931A (ja) 2002-04-02
AU3459599A (en) 1999-10-18
PL201645B1 (pl) 2009-04-30
US20070093530A1 (en) 2007-04-26
JP2003155274A (ja) 2003-05-27
CZ300706B6 (cs) 2009-07-22
US20080214540A1 (en) 2008-09-04
BR9909358A (pt) 2000-12-12
US20030018053A1 (en) 2003-01-23
CN1296485A (zh) 2001-05-23
NO20004900L (no) 2000-10-17
US6426344B2 (en) 2002-07-30
DE69918278D1 (de) 2004-07-29
WO1999050268A3 (en) 1999-12-16
SK7522001A3 (en) 2002-02-05
ES2224632T3 (es) 2005-03-01
KR100584650B1 (ko) 2006-05-30
US20100137301A1 (en) 2010-06-03
OA11622A (en) 2004-09-16
US20120270912A1 (en) 2012-10-25
US6214991B1 (en) 2001-04-10
PL348244A1 (en) 2002-05-20
ID27884A (id) 2001-05-03
CA2383983C (en) 2009-09-29
BG65446B1 (bg) 2008-08-29
TR200002869T2 (tr) 2000-12-21
HUP0101672A2 (hu) 2002-04-29
MXPA02003122A (es) 2004-04-21
HUP0101672A3 (en) 2002-05-28
EP1066283B1 (en) 2004-06-23
AP2000001929A0 (en) 2000-09-30
IL138711A (en) 2006-09-05
TWI243163B (en) 2005-11-11
US7304079B2 (en) 2007-12-04
EP1066283A2 (en) 2001-01-10
ATE269861T1 (de) 2004-07-15
US7105514B2 (en) 2006-09-12
WO1999050268A2 (en) 1999-10-07
BG104819A (en) 2001-05-31
US20040235933A1 (en) 2004-11-25
US20100324039A1 (en) 2010-12-23
NO20004900D0 (no) 2000-09-29
CN1205207C (zh) 2005-06-08
YU59600A (sh) 2002-12-10
US6730794B2 (en) 2004-05-04
CA2383983A1 (en) 1999-10-07
AU774929B2 (en) 2004-07-15
DE69918278T2 (de) 2005-07-14
IL138711A0 (en) 2001-10-31
NZ507172A (en) 2003-10-31
US8163932B2 (en) 2012-04-24
KR20010042330A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
EE200000573A (et) Asendatud indoolalkaanhapped
ATE238984T1 (de) Sulfonylaminocarbonsäuren
ATE341990T1 (de) Sigmidoskop
DE59902874D1 (de) Buchsenkontakt
DE59901560D1 (de) Retrograder tibianagel
TR199800818A3 (tr) Ikame edilmis diaminokarbonik asitler.
PT1240172E (pt) Novos acidos aminopropilfosfinicos
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
DE59907306D1 (de) Fadenchangierung
ID23287A (id) Trisiklik tersubstitusi
DE59906931D1 (de) Exzenterzahnradgetriebe
DE59903966D1 (de) Exzenterzahnradgetriebe
ATE262513T1 (de) Benzoylpyridazine
ID23219A (id) Trisiklik tersubstitusi
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE69809804D1 (de) Notlaufgeländereifen
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59807217D1 (de) Nadellager
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
DE19842103B4 (de) Stanznietzuführung
DE59808995D1 (de) Endomikroskopsystem
DE59903616D1 (de) Rollenwicklerwalze
DE59902088D1 (de) Achrathermer Reimager
DE59900612D1 (de) Dispersionsazofarbstoffmischungen